Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: Evolocumab met the main goal of a late-stage trial titled RUTHERFORD-2 by lowering “bad” LDL cholesterol levels when tested against a placebo on 329 patients. Amgen, the world’s biggest biotechnology company, is testing evolocumab widely on a variety of subpopulations. The RUTHERFORD-2 study included patients with familial hypercholesterolemia, an inherited condition that causes high levels of “bad” LDL cholesterol starting at birth. Specifically, patients in the study had heterozygous familial hypercholesterolemia, which is one of the most common genetic disorders affecting about one out of every 300 to 500 people worldwide, according to Amgen. The company on Tuesday reported positive results from a fourth late-stage study of evolocumab, for which it plans to begin seeking approvals this year. The drug is intended for people who cannot tolerate widely used statins, or who are unable to get their LDL levels low enough despite using high potency statins, such as AstraZeneca’s Crestor. Amgen’s shares closed at $120.89 on the Nasdaq on Thursday.

Output: Amgen's cholesterol fighter succeeds in fifth late-stage study.


Input: Consider Input: The release does not mention cost or whether it’s covered by private insurance or Medicare, and in this case, it’s a pretty big omission. This may be an enormously expensive treatment for patients — and it’s why we have a cost criterion in our reviews. The hopeful psoriasis patient who sees this release without a cost discussion might already have their hand on the phone to call their dermatologist. Here’s a very rough estimate of what that patient might face in terms of cost: Based on a conservative wholesale price of roughly $4,000 per 80 mg injection and following the recommendation (found on the package insert) of two injections every two weeks for 12 weeks, followed by monthly injections, we calculated $48,000 for the first 12 weeks plus $36,000 for the following 9 months or $84,000 total. The release stated that by week 12, “76.4 to 81.8 percent of patients had their psoriasis classified as “clear” or “minimal” compared to 3.2% of patients on the placebo. By the 60th week, 68.7 to 78.3 percent of patients had maintained their improvement.” We also wanted more detail on the measured strength of the response for each patient. For example, what constitutes “minimal”? The release adequately addresses harms and notes that long-term side effects are unknown with this sentence: “Adverse events associated with ixekizumab included slightly higher rates of neutropenia (low white blood cell count), yeast infection and inflammatory bowel disease compared to the placebo. The safety of therapy longer than 60 weeks will need to be monitored in the future.” The release clearly and thoroughly describes the three phase 3 international trials at 21 sites, that they enrolled a large number of patients, and that they were randomized and controlled. There was no disease mongering. The release describes what psoriasis is and its prevalence, and explains that these trials were for moderate to severe psoriasis which covers at least 10 percent of the body. The release is very transparent in stating that the drug manufacturer paid for the research and that the lead researcher is a paid consultant to Eli Lilly. The release did not compare the many different ways that patients treat psoriasis, some with topical agents and some with oral steroids or other medications. The release states that the drug has been approved by the FDA following the completion of the trials. This is a strong indication that the drug is or soon will be available. The release should have noted that the drug is already being marketed under the brand name Taltz. The release makes an understated claim to novelty with this quote from the lead researcher: “Ten years ago, we thought complete clearance of this disease was impossible. It wasn’t something we would even try to do. Now with this drug, we’re obtaining response levels higher than ever seen before.” There was no unjustifiable language in the release.

Output: New drug clears psoriasis in clinical trials


Input: Consider Input: A significant drop in immunisation over the last few years has made Samoa highly vulnerable to outbreaks of the disease, with the World Health Organisation (WHO) saying vaccine coverage is just about 31% there. Schools have been shut and a mass vaccination effort launched in the nation of just 200,000 located south of the equator halfway between Hawaii and New Zealand, with its government saying 50,068 people have been vaccinated. The health ministry said 3,149 cases of measles have been reported, with 213 during the last 24 hours. Of 197 victims in hospital, 20 are critically ill children and three are pregnant women, it added. Deaths in the outbreak have now reached 42, the majority of them children under the age of four, the government said. Neighbouring New Zealand said it was sending more supplies and personnel, including emergency medical assistance teams, nurse vaccinators, intensive care specialists and Samoan-speaking medical professionals. “The Samoan health system is under serious strain with growing numbers of people, many of whom are very young, needing complex care as a result of the measles outbreak,” said New Zealand’s foreign minister, Winston Peters. New Zealand would also fund 100,000 more vaccines for measles and rubella, Peters added in a statement. Britain said a group of British doctors and nurses left on Friday to help Samoa’s efforts to rein in the outbreak, while Australia said it had also sent medical personnel and supplies. Measles is caused by a highly contagious virus that spreads easily through coughing and sneezing. Other nations in the Pacific, such as Tonga and Fiji, are also grappling with a spike in the number of measles cases. Tonga has said its outbreak followed the return of a squad of its rugby players from New Zealand, where Auckland, the biggest city, is tackling a growing number of cases. Measles cases are rising worldwide, even in wealthy nations such as Germany and the United States, as parents shun immunisation for philosophical or religious reasons, or fears, debunked by doctors, that such vaccines could cause autism.


Output: Samoa measles toll hits 42 as nations dispatch medical teams, supplies.